Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083389 | 0.77 | SKP2 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL12802080 | 0.71 | ALDH1A1 (0.36) | USP2ALDH1A1HPGDTDP1TSHR | |
| SCHEMBL17923095 | 0.69 | TSHR (0.41) | USP2ALDH1A1HPGDTDP1ALOX15 | |
| Hydrochloric Acid SCHEMBL1567860 | 0.68 | ALDH1A1 (0.36) | ALDH1A1TDP1TLR8 | |
| SCHEMBL12802125 | 0.67 | TSHR (0.36) | USP2ALDH1A1HPGDTDP1TSHR | |
| SCHEMBL12958717 | 0.66 | PRSS1 (0.36) | ALDH1A1ALOX15TSHR | |
| SCHEMBL4828210 | 0.65 | KDM4E (0.32) | — | |
| SCHEMBL12802111 | 0.65 | HRH3 (0.41) | USP2ALDH1A1HPGDTDP1TSHR | |
| SCHEMBL27603659 | 0.65 | SKP2 (0.42) | ALDH1A1HPGDTDP1TSHR | |
| SCHEMBL8043350 | 0.64 | CRHR1 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | USP2 3808/4885ALDH1A1 807/4885HPGD 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.